Want to see IKT full AI Analyst Report?
IKT Stock Chart & Stats
$1.83
$0.06(1.71%)
At close: 4:00 PM EST
$1.83
$0.06(1.71%)
Day’s Range― - ―
52-Week Range$1.33 - $2.53
Previous CloseN/A
Volume38.02K
Average Volume (3M)1.05M
Market Cap
$301.03M
Enterprise Value$119.11
Total Cash (Recent Filing)$170.37M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Aug 17, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding132,032,640
10 Day Avg. Volume1,384,669
30 Day Avg. Volume1,052,622
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.17
Price to Sales (P/S)0.00
P/FCF Ratio-7.25
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.00Price Target Upside227.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.43
Revenue Forecast (FY)$375.00K
Bulls Say, Bears Say
Bulls Say
Balance-sheet Strength (low Debt, Sizable Equity)The company’s balance sheet shows effectively no debt and substantial equity (~$168M TTM), which materially reduces near-term refinancing risk for a development-stage biotech. This financial cushion supports continued R&D and the pivotal Phase 3 program without immediate reliance on dilutive financing.
Regulatory Progress — FDA Orphan Drug DesignationOrphan Drug Designation provides development incentives (potential tax credits, user-fee exemptions, and possible seven-year market exclusivity) and strengthens regulatory positioning. These structural advantages can lower development costs and improve the long-term commercial and strategic attractiveness of IKT-001 if approved.
Extended Runway From $50M Equity RaiseThe $50M at-the-market financing explicitly extends cash to support operations through the topline readout for Part B of the global Phase 3 IMPROVE-PAH trial. This funded runway reduces near-term refinancing pressure and enables the company to execute the pivotal program, a key structural value inflection.
Bears Say
No Product RevenueThe company currently generates no product revenue, meaning all operations rely on external capital. Absent commercialization, long-term viability depends on clinical success and financing access. This structural revenue gap increases execution risk and extends the timeline to selfsustaining cash generation.
Persistent Cash Burn And Negative Cash FlowSizable negative operating and free cash flow indicate ongoing consumption of cash reserves to fund R&D. Persistent burn raises the probability of future financing needs, increases dilution risk over time, and reduces flexibility to pursue additional programs or respond to trial delays without external funding.
Dilution Risk And Governance ChangesThe recent ATM issuance and shareholder-approved increase in the equity incentive pool materially expand potential share count and near-term dilution. Governance amendments that limit officer liability and increase available equity for grants can preserve management continuity but may dilute existing holders and affect long-term per-share economics.
Inhibikase Therapeutics News
IKT FAQ
What was Inhibikase Therapeutics, Inc.’s price range in the past 12 months?
Inhibikase Therapeutics, Inc. lowest stock price was $1.33 and its highest was $2.53 in the past 12 months.
What is Inhibikase Therapeutics, Inc.’s market cap?
Inhibikase Therapeutics, Inc.’s market cap is $301.03M.
When is Inhibikase Therapeutics, Inc.’s upcoming earnings report date?
Inhibikase Therapeutics, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 16 days.
How were Inhibikase Therapeutics, Inc.’s earnings last quarter?
Inhibikase Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.108 by $0.008.
Is Inhibikase Therapeutics, Inc. overvalued?
According to Wall Street analysts Inhibikase Therapeutics, Inc.’s price is currently Undervalued.
Does Inhibikase Therapeutics, Inc. pay dividends?
Inhibikase Therapeutics, Inc. does not currently pay dividends.
What is Inhibikase Therapeutics, Inc.’s EPS estimate?
Inhibikase Therapeutics, Inc.’s EPS estimate is -0.11.
How many shares outstanding does Inhibikase Therapeutics, Inc. have?
Inhibikase Therapeutics, Inc. has 132,032,640 shares outstanding.
What happened to Inhibikase Therapeutics, Inc.’s price movement after its last earnings report?
Inhibikase Therapeutics, Inc. reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.108. Following the earnings report the stock price went down -1.042%.
Which hedge fund is a major shareholder of Inhibikase Therapeutics, Inc.?
Currently, no hedge funds are holding shares in IKT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inhibikase Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (227.87% Upside)
$6.00 (227.87% Upside)
Blogger Sentiment
Bullish
IKT Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.76%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
83.85%
Trailing 12-Months
Company Description
Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
IKT Stock 12 Month Forecast
Average Price Target
$6.00
▲(227.87% Upside)
Technical Analysis
Atossa Therapeutics
―
Anixa Biosciences
―
Spero Therapeutics
―
Surrozen
―
TScan Therapeutics
―
Ownership Overview
17.58% Insiders
5.43% Mutual Funds
0.14% Other Institutional Investors
68.66% Public Companies and
Individual Investors